Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: A cross-over randomised controlled trial

Research - Open Access
George BardsleyPeter DaleyYatesAmanda BainesRodger KempsfordMathew WilliamsTony MallonIrene BraithwaiteKylie RiddellShashidhar JoshiPhilippe BareilleRichard BeasleyJames Fingleton on behalf of the study team

Abstract

Background

Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action.

Methods

A single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study was undertaken in 28 steroid-naïve adults with asthma. Participants with an FEV1 ≥ 60% predicted, reversible airway disease, and FeNO > 40 ppb received FF/VI 100/25 mcg or placebo once daily for 14 days. FeNO and peak expiratory flow were measured twice-daily during treatment and during a 21-day washout period. FEV1 was measured for five days from treatment cessation. The primary outcome measure was FeNO change from baseline ratio for 21 days following treatment cessation.

Results

In the 27 subjects who completed the study, median (range) baseline FeNO was 87 ppb (42–212). FF/VI 100/25 mcg reduced FeNO by day 3, ratio FF/VI versus placebo 0.72 (95% confidence interval 0.61–0.86) with the maximum reduction occurring at day 14, 0.32 (0.27–0.37). Following cessation of treatment FeNO remained suppressed for 18 days, ratio on day 18 0.77 (0.59–1.00), whereas improvements in FEV1 and peak flow were maintained for 3 to 4 days post-treatment.

Conclusions

The anti-inflammatory duration of action of FF/VI is consistent with the high glucocorticoid receptor affinity and long lung retention of fluticasone furoate. The anti-inflammatory effect of FF/VI was of greater duration than its bronchodilator effect in adults with mild asthma.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: WORLD ALLERGY CONGRESS | WAC2019 - WORLD ALLERGY CONGRESS https://t.co/KpUHk6kq9r, see more https://t.co/CpGiFuOOYd
4hreplyretweetfavorite
Interasma RT @worldallergy: Top story: Conjunctivitis Seen in Patients on Dupixent | Medpage Today https://t.co/WzoMs3nmNr, see more https://t.co/yY2
10hreplyretweetfavorite
Interasma RT @WAOJM: Beirut, Lebanon - 4-6 April 2019 Visit the WISC 2019 Website for details! https://t.co/Hz6qBiFuIm
10hreplyretweetfavorite
Interasma RT @AllergyEaaci: How to discontinue omalizumab in chronic spontaneous urticaria? Download Article Here: https://t.co/CnLrzLyZ4J #allergy #…
10hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma